𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women

✍ Scribed by Aydiner, Adnan

Book ID
120461932
Publisher
Elsevier Science
Year
2013
Tongue
English
Weight
304 KB
Volume
22
Category
Article
ISSN
0960-9776

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Do adjuvant aromatase inhibitors increas
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer : Meta-analysis of randomized trials
✍ Federica Cuppone; Emilio Bria; Sunil Verma; Kathleen I. Pritchard; Sonal Gandhi; πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 203 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. Despite the advantages from using aromatase inhibitors (AIs) compared with tamoxifen for early breast cancer, an unexpectedly greater number of grade 3 and 4 cardiovascular events (CVAE) (as defined by National Cancer Institute of Canada‐Common Toxicity Criteria [version

Summary of aromatase inhibitor clinical
Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer
✍ Aman U. Buzdar; R. Charles Coombes; Paul E. Goss; Eric P. Winer πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 115 KB

Five years of adjuvant therapy with tamoxifen was considered the gold-standard treatment for postmenopausal women with estrogen receptor-positive breast cancer for many years. Data from a core group of clinical trials investigating the safety and efficacy of aromatase inhibitors (AIs) have challenge